Genotype-Phenotype Studies in Bipolar Disorder Showing Association Between the DAOA/G30 Locus and Persecutory Delusions: A First Step Toward a Molecular Genetic Classification of Psychiatric Phenotypes

2005 ◽  
Vol 162 (11) ◽  
pp. 2101-2108 ◽  
Author(s):  
Thomas G. Schulze ◽  
Stephanie Ohlraun ◽  
Piotr M. Czerski ◽  
Johannes Schumacher ◽  
Layla Kassem ◽  
...  
2019 ◽  
Vol 19 (5) ◽  
pp. 412-416 ◽  
Author(s):  
Emanuela Molinari ◽  
Olimpia E Curran ◽  
Robin Grant

In 2016, the WHO incorporated molecular markers, in addition to histology, into the diagnostic classification of central nervous system (CNS) tumours. This improves diagnostic accuracy and prognostication: oligo-astrocytoma no longer exists as a clinical entity; isocitrate dehydrogenase (IDH) mutant and 1p/19q co-deleted oligodendroglioma is a smaller category with better prognosis; IDH wild-type ‘low-grade’ glioma has a much poorer prognosis; and glioblastoma is divided into IDH mutant (with an better prognosis than pre-2016 glioblastoma) and IDH wild type (with a poorer prognosis). Previous advice based on phenotype alone will change with respect to median survival, best management plan and response to treatment. There are implications for routine neuropathology reporting and future trial design. Cases that are difficult to classify may need more advanced molecular genetic classification through DNA methylation-based classification of CNS tumours (Heidelberg Classifier). We discuss the practical implications.


2017 ◽  
Vol 37 (3) ◽  
pp. 431-448 ◽  
Author(s):  
Michael T. Tetzlaff ◽  
Alexandre Reuben ◽  
Steven D. Billings ◽  
Victor G. Prieto ◽  
Jonathan L. Curry

1989 ◽  
Vol 11 (1) ◽  
pp. 116
Author(s):  
Carolyn A. Felix ◽  
Ilan R. Kirsch ◽  
Gregory H. Reaman ◽  
Stanley K. Korsmeyer ◽  
Diane E. Cole ◽  
...  

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Laurent James Livermore ◽  
Martin Isabelle ◽  
Ian Mac Bell ◽  
Connor Scott ◽  
John Walsby-Tickle ◽  
...  

Abstract Background The molecular genetic classification of gliomas, particularly the identification of isocitrate dehydrogenase (IDH) mutations, is critical for clinical and surgical decision-making. Raman spectroscopy probes the unique molecular vibrations of a sample to accurately characterize its molecular composition. No sample processing is required allowing for rapid analysis of tissue. The aim of this study was to evaluate the ability of Raman spectroscopy to rapidly identify the common molecular genetic subtypes of diffuse glioma in the neurosurgical setting using fresh biopsy tissue. In addition, classification models were built using cryosections, formalin-fixed paraffin-embedded (FFPE) sections and LN-18 (IDH-mutated and wild-type parental cell) glioma cell lines. Methods Fresh tissue, straight from neurosurgical theatres, underwent Raman analysis and classification into astrocytoma, IDH-wild-type; astrocytoma, IDH-mutant; or oligodendroglioma. The genetic subtype was confirmed on a parallel section using immunohistochemistry and targeted genetic sequencing. Results Fresh tissue samples from 62 patients were collected (36 astrocytoma, IDH-wild-type; 21 astrocytoma, IDH-mutated; 5 oligodendroglioma). A principal component analysis fed linear discriminant analysis classification model demonstrated 79%–94% sensitivity and 90%–100% specificity for predicting the 3 glioma genetic subtypes. For the prediction of IDH mutation alone, the model gave 91% sensitivity and 95% specificity. Seventy-nine cryosections, 120 FFPE samples, and LN18 cells were also successfully classified. Meantime for Raman data collection was 9.5 min in the fresh tissue samples, with the process from intraoperative biopsy to genetic classification taking under 15 min. Conclusion These data demonstrate that Raman spectroscopy can be used for the rapid, intraoperative, classification of gliomas into common genetic subtypes.


Sign in / Sign up

Export Citation Format

Share Document